ロード中...
Cost-effectiveness analysis comparing “PARP inhibitors-for-all” to the biomarker-directed use of PARP inhibitor maintenance therapy for newly diagnosed advanced stage ovarian cancer
OBJECTIVES. Clinical trials evaluating universal PARP inhibitor (PARPi) frontline maintenance therapy for advanced stage ovarian cancer have reported progression-free survival (PFS) benefit. It is unclear whether PARPi maintenance therapy will universally enhance value (clinical benefits relative to...
保存先:
| 出版年: | Gynecol Oncol |
|---|---|
| 主要な著者: | , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8086124/ https://ncbi.nlm.nih.gov/pubmed/32863036 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2020.08.003 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|